QILIAN INTERNATIONAL HOLDING (QLI)
KYG7307E1070 - Common Stock
We assign a fundamental rating of 2 out of 10 to QLI. QLI was compared to 197 industry peers in the Pharmaceuticals industry. The financial health of QLI is average, but there are quite some concerns on its profitability. QLI does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
QLI had negative earnings in the past year.
QLI had a positive operating cash flow in the past year.
QLI had positive earnings in 4 of the past 5 years.
QLI had a positive operating cash flow in 4 of the past 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of -15.18%, QLI is in the better half of the industry, outperforming 68.21% of the companies in the same industry.
QLI's Return On Equity of -18.18% is fine compared to the rest of the industry. QLI outperforms 75.90% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -15.18% | ||
| ROE | -18.18% | ||
| ROIC | N/A |
ROA(3y)-3.11%
ROA(5y)3.26%
ROE(3y)-3.47%
ROE(5y)7.16%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
QLI's Gross Margin of 3.77% is in line compared to the rest of the industry. QLI outperforms 48.21% of its industry peers.
In the last couple of years the Gross Margin of QLI has declined.
QLI does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 3.77% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-37%
GM growth 5Y-25.24%
2. Health
2.1 Basic Checks
QLI does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, QLI has about the same amount of shares outstanding.
The number of shares outstanding for QLI has been increased compared to 5 years ago.
The debt/assets ratio for QLI has been reduced compared to a year ago.
2.2 Solvency
An Altman-Z score of 3.37 indicates that QLI is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 3.37, QLI is in the better half of the industry, outperforming 78.46% of the companies in the same industry.
QLI has a Debt/Equity ratio of 0.01. This is a healthy value indicating a solid balance between debt and equity.
QLI has a Debt to Equity ratio (0.01) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.01 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 3.37 |
ROIC/WACCN/A
WACC7.23%
2.3 Liquidity
QLI has a Current Ratio of 5.18. This indicates that QLI is financially healthy and has no problem in meeting its short term obligations.
QLI's Current ratio of 5.18 is fine compared to the rest of the industry. QLI outperforms 68.21% of its industry peers.
QLI has a Quick Ratio of 4.43. This indicates that QLI is financially healthy and has no problem in meeting its short term obligations.
QLI has a Quick ratio of 4.43. This is in the better half of the industry: QLI outperforms 62.56% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.18 | ||
| Quick Ratio | 4.43 |
3. Growth
3.1 Past
The earnings per share for QLI have decreased strongly by -825.47% in the last year.
The Revenue for QLI has decreased by -28.35% in the past year. This is quite bad
The Revenue has been decreasing by -1.60% on average over the past years.
EPS 1Y (TTM)-825.47%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q-871.67%
Revenue 1Y (TTM)-28.35%
Revenue growth 3Y-2.43%
Revenue growth 5Y-1.6%
Revenue growth Q2Q-47.18%
3.2 Future
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for QLI. In the last year negative earnings were reported.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A
5. Dividend
5.1 Amount
No dividends for QLI!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
QILIAN INTERNATIONAL HOLDING
NASDAQ:QLI (5/17/2024, 7:22:18 PM)
0.6816
-0.03 (-4.8%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap24.37M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -15.18% | ||
| ROE | -18.18% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 3.77% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.91
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.01 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 5.18 | ||
| Quick Ratio | 4.43 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-825.47%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next YN/A
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-28.35%
Revenue growth 3Y-2.43%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y